Yale University-ko ikertzaileekin lankidetzan egindako argitalpenak (29)

2024

  1. Developmental or Procedural Vena Cava Interruption and Venous Thromboembolism: A Review

    Seminars in Thrombosis and Hemostasis, Vol. 50, Núm. 6, pp. 851-865

  2. Fibrinolytic Agents in Thromboembolic Diseases: Historical Perspectives and Approved Indications

    Seminars in Thrombosis and Hemostasis, Vol. 50, Núm. 5, pp. 773-789

  3. Optimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease

    Nature Reviews Cardiology, Vol. 21, Núm. 8, pp. 574-592

  4. Validating International Classification of Diseases Code 10th Revision algorithms for accurate identification of pulmonary embolism

    Journal of Thrombosis and Haemostasis

  5. When Direct Oral Anticoagulants Should Not Be Standard Treatment: JACC State-of-the-Art Review

    Journal of the American College of Cardiology, Vol. 83, Núm. 3, pp. 444-465

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Atorvastatin versus Placebo in ICU Patients with COVID-19: Ninety-day Results of the INSPIRATION-S Trial

    Thrombosis and haemostasis, Vol. 123, Núm. 7, pp. 723-733

  3. Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes: Meta-Analysis of Randomized Trials

    Journal of the American College of Cardiology, Vol. 81, Núm. 1, pp. 16-30

  4. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

  5. Sex-Related Differences in Patient Characteristics, Risk Factors, and Symptomatology in Older Adults with Pulmonary Embolism: Findings from the SERIOUS-PE Study

    Seminars in Thrombosis and Hemostasis, Vol. 49, Núm. 7, pp. 725-735

2022

  1. Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial

    The BMJ, Vol. 376

  2. Catheter-Directed Thrombolysis vs Anticoagulation in Patients with Acute Intermediate-High-risk Pulmonary Embolism: The CANARY Randomized Clinical Trial

    JAMA Cardiology, Vol. 7, Núm. 12, pp. 1189-1197

  3. Developing Validated Tools to Identify Pulmonary Embolism in Electronic Databases: Rationale and Design of the PE-EHR+ Study

    Thrombosis and Haemostasis, Vol. 123, Núm. 6, pp. 649-662

  4. Durable functional limitation in patients with coronavirus disease-2019 admitted to intensive care and the effect of intermediate-dose vs standard-dose anticoagulation on functional outcomes

    European Journal of Internal Medicine, Vol. 103, pp. 76-83

  5. Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review

    JAMA Cardiology, Vol. 7, Núm. 7, pp. 747-759

  6. Sex Differences in PrEsentation, Risk Factors, Drug and Interventional Therapies, and OUtcomes of Elderly PatientS with Pulmonary Embolism: Rationale and design of the SERIOUS-PE study

    Thrombosis Research, Vol. 214, pp. 122-131

  7. Women's representation in venous thromboembolism randomized trials and registries: The illustrative example of direct oral anticoagulants for acute treatment

    Contemporary Clinical Trials, Vol. 115

2021

  1. Cerebral Venous Sinus Thrombosis in the U.S. Population, After Adenovirus-Based SARS-CoV-2 Vaccination, and After COVID-19

    Journal of the American College of Cardiology, Vol. 78, Núm. 4, pp. 408-411

  2. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality among Patients with COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial

    JAMA - Journal of the American Medical Association, Vol. 325, Núm. 16, pp. 1620-1630

  3. Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial

    Thrombosis and Haemostasis, Vol. 122, Núm. 1, pp. 131-141